According to GlobalData’s company profile on Galecto, NSAID cancer drugs was a key innovation area identified from patents. Galecto's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11827666B2) discloses a series of D-galactopyranose compounds with specific structural variations, aimed at targeting disorders related to the binding of galectin-1 to a ligand in mammals. The compounds described in the patent encompass various substitutions on the D-galactopyranose backbone, including different phenyl and pyridinyl groups, as well as specific halogen and alkyl substitutions. These compounds are intended for use in pharmaceutical compositions along with pharmaceutically acceptable additives.

Furthermore, the patent claims a method for treating a range of disorders associated with galectin-1 binding in mammals. These disorders include inflammation, fibrosis, cancer, autoimmune diseases, heart disease, metabolic disorders, and various other conditions related to abnormal scar formation, angiogenesis, and organ-specific diseases. The method involves administering a therapeutically effective amount of the disclosed compounds to mammals in need of treatment for the specified disorders. The compounds are proposed to have potential applications in addressing a wide array of medical conditions, from cancer and autoimmune diseases to metabolic disorders and lung diseases, highlighting the broad therapeutic scope of the patented compounds.

To know more about GlobalData’s detailed insights on Galecto, buy the report here.